New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
07:13 EDTGWPHGW Pharmaceuticals reports promising signs of efficacy, safety in CBD candidate
GW Pharmaceuticals announced physician reports of efficacy and safety data on 27 children and young adults with treatment-resistant epilepsy who have been treated with GW's investigational cannabidiol, or CBD, product candidate, Epidiolex, for a period of 12 weeks. The treatment-resistant patients suffer from a range of epilepsies in which current anti-epileptic drugs have been unsuccessful in adequately controlling seizures, and included such severe forms of epilepsy as Dravet syndrome and Lennox-Gastaut syndrome. Uncontrolled data from two hospital sites in the United States that were generated under expanded access Investigational New Drug applications authorized by the FDA were made available to the company.
News For GWPH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 11, 2015
11:24 EDTGWPHGW Pharmaceuticals remains a top mid-cap pick at Piper Jaffray
Subscribe for More Information
11:21 EDTGWPHGW Pharmaceuticals declined partnership offers, Bloomberg reports
Subscribe for More Information
10:29 EDTGWPHFMR reports 10% passive stake in GW Pharmaceuticals
07:32 EDTGWPHGW Pharmaceuticals initiates Phase 3 study of Epidiolex
Subscribe for More Information
07:31 EDTGWPHGW Pharmaceuticals reports Q2 EPS (5c) , may not compare to one estimate ($1.12)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use